Cargando…

Serum and follicular fluid chemerin and chemerin mRNA expression in women with polycystic ovary syndrome: Systematic review and meta‐analysis

INTRODUCTION: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. Chemerin, a novel adipokine, is involved in inflammation, energy metabolism, adipogenesis, angiogenesis and insulin secretion in the adipose cells and ovary. This systematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansoori, Anahita, Amoochi‐Foroushani, Golnaz, Zilaee, Marzie, Hosseini, Seyed Ahmad, Azhdari, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754250/
https://www.ncbi.nlm.nih.gov/pubmed/34699139
http://dx.doi.org/10.1002/edm2.307
_version_ 1784632232427651072
author Mansoori, Anahita
Amoochi‐Foroushani, Golnaz
Zilaee, Marzie
Hosseini, Seyed Ahmad
Azhdari, Maryam
author_facet Mansoori, Anahita
Amoochi‐Foroushani, Golnaz
Zilaee, Marzie
Hosseini, Seyed Ahmad
Azhdari, Maryam
author_sort Mansoori, Anahita
collection PubMed
description INTRODUCTION: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. Chemerin, a novel adipokine, is involved in inflammation, energy metabolism, adipogenesis, angiogenesis and insulin secretion in the adipose cells and ovary. This systematic review with meta‐analysis aimed to compare serum and follicular fluid (FF) chemerin and ovarian chemerin mRNA expression among women with PCOS and non‐PCOS. METHODS: Electronic databases including Web of Science, PubMed, Google Scholar, Scopus, Cochrane and CINAHL were used for a comprehensive search through April 2021. Of the 174 articles initially identified, 22 studies met the eligibility criteria. A random‐effects model with a weighted mean difference (WMD) and 95% confidence interval (CI) was performed to compare the outcomes between groups. Subgroup and sensitivity analyses were performed to detect the sources of heterogeneity. RESULTS: Women with PCOS compared to without PCOS showed significantly higher serum chemerin [WMD: 12.02 pg/ml (95% CI: [10.92, 13.13]), p < .001], chemerin mRNA expression [WMD: 0.38% (95% CI [0.25, 0.52]), p = .001] and FF chemerin [(WMD): 41.7 pg/ml (95% CI [17.89, 65.5]) p < .001]. Further, serum chemerin remained high in PCOS women even with subgroup analysis based on body mass index (BMI) or sample size (p < .001). Serum chemerin was higher in women with PCOS and higher BMI [(WMD): 3.29 pg/ml (95% CI: [2.73, 3.384]), p < .001]. The expression of chemerin mRNA was significantly higher in the PCOS group compared to the control group [WMD: 0.38% (95% CI [0.25, 0.52]), p < .001]. CONCLUSION: Serum and FF chemerin and mRNA expression were higher in the PCOS group compared to the controls. Further, serum chemerin was higher in PCOS women with higher BMI compared to lower BMI. The present findings illustrate that chemerin may be associated with PCOS status and BMI, independently.
format Online
Article
Text
id pubmed-8754250
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87542502022-01-19 Serum and follicular fluid chemerin and chemerin mRNA expression in women with polycystic ovary syndrome: Systematic review and meta‐analysis Mansoori, Anahita Amoochi‐Foroushani, Golnaz Zilaee, Marzie Hosseini, Seyed Ahmad Azhdari, Maryam Endocrinol Diabetes Metab Reviews INTRODUCTION: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. Chemerin, a novel adipokine, is involved in inflammation, energy metabolism, adipogenesis, angiogenesis and insulin secretion in the adipose cells and ovary. This systematic review with meta‐analysis aimed to compare serum and follicular fluid (FF) chemerin and ovarian chemerin mRNA expression among women with PCOS and non‐PCOS. METHODS: Electronic databases including Web of Science, PubMed, Google Scholar, Scopus, Cochrane and CINAHL were used for a comprehensive search through April 2021. Of the 174 articles initially identified, 22 studies met the eligibility criteria. A random‐effects model with a weighted mean difference (WMD) and 95% confidence interval (CI) was performed to compare the outcomes between groups. Subgroup and sensitivity analyses were performed to detect the sources of heterogeneity. RESULTS: Women with PCOS compared to without PCOS showed significantly higher serum chemerin [WMD: 12.02 pg/ml (95% CI: [10.92, 13.13]), p < .001], chemerin mRNA expression [WMD: 0.38% (95% CI [0.25, 0.52]), p = .001] and FF chemerin [(WMD): 41.7 pg/ml (95% CI [17.89, 65.5]) p < .001]. Further, serum chemerin remained high in PCOS women even with subgroup analysis based on body mass index (BMI) or sample size (p < .001). Serum chemerin was higher in women with PCOS and higher BMI [(WMD): 3.29 pg/ml (95% CI: [2.73, 3.384]), p < .001]. The expression of chemerin mRNA was significantly higher in the PCOS group compared to the control group [WMD: 0.38% (95% CI [0.25, 0.52]), p < .001]. CONCLUSION: Serum and FF chemerin and mRNA expression were higher in the PCOS group compared to the controls. Further, serum chemerin was higher in PCOS women with higher BMI compared to lower BMI. The present findings illustrate that chemerin may be associated with PCOS status and BMI, independently. John Wiley and Sons Inc. 2021-10-26 /pmc/articles/PMC8754250/ /pubmed/34699139 http://dx.doi.org/10.1002/edm2.307 Text en © 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Mansoori, Anahita
Amoochi‐Foroushani, Golnaz
Zilaee, Marzie
Hosseini, Seyed Ahmad
Azhdari, Maryam
Serum and follicular fluid chemerin and chemerin mRNA expression in women with polycystic ovary syndrome: Systematic review and meta‐analysis
title Serum and follicular fluid chemerin and chemerin mRNA expression in women with polycystic ovary syndrome: Systematic review and meta‐analysis
title_full Serum and follicular fluid chemerin and chemerin mRNA expression in women with polycystic ovary syndrome: Systematic review and meta‐analysis
title_fullStr Serum and follicular fluid chemerin and chemerin mRNA expression in women with polycystic ovary syndrome: Systematic review and meta‐analysis
title_full_unstemmed Serum and follicular fluid chemerin and chemerin mRNA expression in women with polycystic ovary syndrome: Systematic review and meta‐analysis
title_short Serum and follicular fluid chemerin and chemerin mRNA expression in women with polycystic ovary syndrome: Systematic review and meta‐analysis
title_sort serum and follicular fluid chemerin and chemerin mrna expression in women with polycystic ovary syndrome: systematic review and meta‐analysis
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754250/
https://www.ncbi.nlm.nih.gov/pubmed/34699139
http://dx.doi.org/10.1002/edm2.307
work_keys_str_mv AT mansoorianahita serumandfollicularfluidchemerinandchemerinmrnaexpressioninwomenwithpolycysticovarysyndromesystematicreviewandmetaanalysis
AT amoochiforoushanigolnaz serumandfollicularfluidchemerinandchemerinmrnaexpressioninwomenwithpolycysticovarysyndromesystematicreviewandmetaanalysis
AT zilaeemarzie serumandfollicularfluidchemerinandchemerinmrnaexpressioninwomenwithpolycysticovarysyndromesystematicreviewandmetaanalysis
AT hosseiniseyedahmad serumandfollicularfluidchemerinandchemerinmrnaexpressioninwomenwithpolycysticovarysyndromesystematicreviewandmetaanalysis
AT azhdarimaryam serumandfollicularfluidchemerinandchemerinmrnaexpressioninwomenwithpolycysticovarysyndromesystematicreviewandmetaanalysis